Navigation Links
Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018
Date:8/11/2009

WALTHAM, Mass., Aug. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry and uptake of premium-priced biologics will drive the systemic lupus erythematosus drug market to more than quadruple from approximately $420 million in 2008 to nearly $2 billion in 2018.

The new Pharmacor report entitled Systemic Lupus Erythematosus finds that the primary drivers of market growth will be the entry and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, Biogen Idec/Roche's ocrelizumab, and Immunomedics/UCB's epratuzumab. In 2018, these three agents, combined with the continued uptake of rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan, Roche's MabThera), will account for more than 80 percent of sales in the systemic lupus erythematosus drug market. In 2008, the market was characterized by extensive use of generics and the majority of sales were driven by the off-label use of two branded agents -- Roche/Galenica's CellCept and rituximab. The off-label use of CellCept, rituximab and other therapies exemplifies the unusual dynamics of the systemic lupus erythematosus market.

"The continued uptake of rituximab, despite its failure in recent clinical trials, highlights the significant challenges associated with drug development for systemic lupus erythematosus, the high unmet need in the indication and the unusual dynamics of this market," said Decision Resources Analyst Dancella Fernandes, Ph.D. "Rituximab's contribution to growth will be greater in the near-term but, from 2013 to 2018, its sales will decline modestly as biosimilar versions of the drug emerge in Europe in 2013 and in the United States in 2015."

The report also finds that the partial replacement of current, predominantly generic, immunosuppressants by branded, premium-priced immunosuppressants will also contribute to market growth. Novartis's Myfortic and Roche/Galenica's CellCept will take market share away from GlaxoSmithKline/Prometheus's Imuran as maintenance treatments as well as Bristol-Myers Squibb's Cytoxan as induction treatments.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                       Decision Resources, Inc.
    Christopher Comfort                      Elizabeth Marshall
    781-296-2597                             781-296-2563
    ccomfort@dresources.com                  emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
2. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
3. China Biologic Products Hosts its First Forum for Strategy and Development
4. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
5. MicroFluidic Systems (MFSI) Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis.
6. CQ Forum on Biosimilar Biological Products - Wed., June 17, 2009
7. China Biologic Products Closes the $9.6 Million Private Placement
8. China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million
9. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
10. Results From Neurotechs NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors
11. Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... 2017   Valentin A. Pavlov, PhD , associate ... and CEO of The Feinstein Institute for Medical ... how the nervous system regulates the immune system, which ... medicine devices to treat disease and injury. The ... The paper examines various studies which further ...
(Date:1/13/2017)... 2017 Research and Markets has announced the ... Global Forecast to 2021" report to their offering. ... The biosimilars market is ... Billion in 2016, at a CAGR of 26.3%. ... manufacturing type, and application. Factors such as rising incidence of various ...
(Date:1/12/2017)... ... January 12, 2017 , ... MEXICO’S FIRST ... Inc., announces the successful outcome of the first lumbar fusion procedure in ... Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical Technologies to ...
(Date:1/12/2017)... , January 12, 2017 The ... world,s biggest facility for producing mycorrhizae. The Centre for ... tapping potential of mycorrhizae and developed a technology that ... ... The TERI facility has a ...
Breaking Biology Technology:
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/15/2016)... LONDON , Dec. 15, 2016 /PRNewswire/ ... the driving experience, health wellness and wellbeing ... As one in three new passenger vehicles ... voice recognition, gesture recognition, heart beat monitoring, ... eyelid monitoring, facial monitoring, and pulse detection. ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
Breaking Biology News(10 mins):